Our findings demonstrate that P-S possesses considerable efficacy in the pre-clinical models of pancreatic cancer while being apparently safe, establish that NFATc1 is a critical factor in mediating drug resistance in pancreatic cancer, and that targeting NFATc1 improves tumor response to chemotherapeutic drugs, including P-S. This evidence concerns the gene NFATC1 and pancreatic neoplasm.